Chart: Current Class Of Risk Evaluation & Mitigation Strategires
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Cymbalta Pregnancy Risk Fit FDA's New Power To Mandate Post-Market Study
FDA's application of its new ability to require - as opposed to request - post-marketing studies under the FDA Amendments Act is on display in the review of a fibromyalgia claim for Lilly's Cymbalta (duloxetine)
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011